common.study.topics.clinical

Treatment of Graves' Ophthalmopathy

common.study.values.description

ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO patients. In addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction in anti-TSHR IgG

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - RVT-1401 (Administered via subcutaneous injection)

RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.

Placebo (Administered via subcutaneous injection)

Placebo

participant.views.study.view.additional

participant.views.study.view.scientific-title

ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy

common.study.values.clinical-trial-id

NCT03938545

participant.views.study.view.id

av2kna